Clik here to view.
Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Clik here to view.
Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer
BASEL, Switzerland Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announced...
View ArticleClik here to view.
CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc., (“CANbridge,”1228.HK) a leading China-based global biopharmaceutical company committed to the research, development and...
View ArticleClik here to view.
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and...
View ArticleClik here to view.
Exscientia 将出席美银证券 2022 年医疗保健大会
英格兰牛津 (美国商业资讯) — Exscientia（纳斯达克：EXAI）今天宣布，公司首席财务官兼首席战略官Ben Taylor和首席技术官Garry Pairaudeau将于太平洋时间2022年5月10日星期二下午5点20分参加美银证券 2022年医疗保健大会的炉边谈话。 炉边谈话的网络直播可在该公司网站的“投资者和媒体...
View ArticleClik here to view.
エクセンシアがBofAセキュリティーズ2022年ヘルスケアカンファレンスで講演へ
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）は本日、2022年5月10日（火）午後5時20分（PT）開催のBofAセキュリティーズ2022年ヘルスケアカンファレンスで、最高財務責任者（CFO）兼最高戦略責任者（CSO）のベン・テイラーと最高技術責任者（CTO）のGarry Pairaudeauが炉辺会議に出席すると発表しました。...
View ArticleClik here to view.
Microba Accelerates Cancer Program With New Leads
BRISBANE, Australia Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program...
View ArticleClik here to view.
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult...
View ArticleClik here to view.
突破性的研究合作：Medi-Globe Group和斯特拉斯堡的IHU将开发世界首款检测胰腺疾病的人工智能软件
德国阿亨穆勒 (美国商业资讯)–Medi-Globe Group已经与斯特拉斯堡的法国医院大学研究所(IHU)达成了一项开创性的研究合作。合作目的是开发出世界上第一款在内窥镜超声检查中检测胰腺疾病的人工智能软件。Medi-Globe Group作为IHU的工业合作伙伴，将进一步扩大其作为微创诊断和治疗领域创新领导者的影响。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Alentis Therapeutics任命Andrea Pellacani博士为首席医疗官
瑞士巴塞尔 (美国商业资讯)–Alentis Therapeutics（以下简称“Alentis ”或 “该公司”）是一家针对器官纤维化和纤维化相关癌症开发突破性疗法的生物技术公司。该公司今天宣布任命Andrea Pellacani博士为首席医疗官。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
BeiGene Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative...
View ArticleClik here to view.
Rhizen...
スイス・バーゼル （ビジネスワイヤ） — スイスに拠点を置く非公開の臨床段階バイオ製薬企業であるRhizen Pharmaceuticals AG（Rhizen）は本日、2022年5月3～5日にドイツのベルリンで開催される欧州臨床腫瘍学会（ESMO）乳がん学会議において、局所進行性／転移性乳がん患者を対象に進行中のテナリシブ第2相試験から得た有望な中間データを報告すると発表しました。...
View ArticleClik here to view.
Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib...
瑞士巴塞尔 (美国商业资讯)–总部位于瑞士的私人控股临床阶段生物制药公司Rhizen Pharmaceuticals AG (Rhizen)今天宣布，公司正在2022年5月3日至5日在德国柏林召开的欧洲肿瘤内科学会(ESMO)乳腺癌会议上公布一项进行中的Tenalisib治疗局部晚期或转移性乳腺癌患者II期试验的中期积极数据。...
View ArticleClik here to view.
Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study to evaluate the safety,...
View ArticleClik here to view.
Elpiscience Announces FDA IND Clearance of ES014, a First-in-Class...
SHANGHAI & SUZHOU, China & GERMANTOWN, Md. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation...
View ArticleClik here to view.
武田薬品工業：2021年度は力強い業績を達成、2022年度も成長の勢いは継続の見込み
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TOKYO：4502/NYSE:TAK）は、本日、2021年度の業績を公表しましたのでお知らせします。成長製品の伸長、新製品の上市ならびに主要なビジネス領域全体での成長が牽引し、力強い業績を達成しました。 当社代表取締役社長CEOのクリストフ・ウェバー（Christophe Weber）は次のように述べています。...
View ArticleClik here to view.
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in...
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product...
View ArticleClik here to view.
Propanc Biopharma Offers a Novel Way to Stop Cancer
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical...
SAN DIEGO Crown Bioscience and Medical & Biological Laboratories (MBL), JSR Life Sciences companies, today announced the formation of a joint venture, to further expand the provision of Crown...
View Article